Globe News Wire
19 Apr 2026, 22:00 UTC · 21w ago
Verdict
Headline takes no side. We score XENE +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Xenon Pharmaceuticals' Azetukalner demonstrated a 53.2% reduction in monthly seizure frequency compared to 10.4% for placebo in the X-TOLE2 study.
More positive than 98% of claims this week
Long-term data show nearly 40% of participants achieved at least 12 months of seizure freedom over a 48-month period.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 91% of claims this week
Azetukalner does not require titration for seizure management.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
Positive clinical data showing significant reductions in seizure frequency for its drug Azetukalner.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
1d ago
−32.4%
Price is moving against the score
$40.35 vs $59.70 close before publication (Apr 17) · not market-adjusted
XENE chart →
